Oncology Central

Is minimal residual disease a convincing tool to determine the treatment duration of immune checkpoint inhibitors?


The treatment armamentarium of cancer has evolved tremendously in the last decades with the concept of targeted drugs . Immune checkpoint inhibitors (ICI) is a targeted treatment that deactivates the tumor-induced inhibition of the immune system . Unfortunately, ICI are administered continuously until disease progression or occurrence of limiting toxicity in view of the absence of data that specifies the length of ICI administration. The toxicity profile of ICI depends on the type of inhibitor used. 

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.